RGNX falls 23% premarket on FDA headlines
RGNX shares fall 23% in premarket trading after FDA headlines, with no further catalyst provided in the wire.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.